Business Plan Executive Summary

Biohope is a start-up biomedical company focused in the research and development of novel clinical management tools.

MAJOR MILESTONES BUSINESS MODEL STRATEGYMANAGEMENTBUSINESS PLANCONCLUSIONS

Contents:PROBLEMSOLUTIONMARKET SIZEPRODUCTCOMPETITION

Problem | CHRONIC INFLAMMATORY CONDITIONS

RENAL TRANSPLANT RHEUMATOID ARTHRITIS

With deficient clinical evolution in transplants show a clear resistance to the drugs they take.

Have bad clinical evolution, ending with di�erent types of disabilities.

Are LOST in 10 years due to rejection.

60%of

patients

50%of

transplantedorgans

years

Of life expectancy can be lost.

4-10

30%of

patients

Problem | AN UNMET MEDICAL NEED IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES

NO personalization,NO precision

Treatment with immunosuppressive and/or immunomodulatory therapies.

Generalguidelines and recommendations.

Loss of time and accuracyIncreased health costsIncreased side e�ects due to suboptimal medicationWorsening of the prognosis

The Solution | IMMUNOBIOGRAM®

Better clinicaloutcomes

Reduction ofside e�ects

Improve patientquality of life

Reduction ofhealth costs

A disruptive blood-based in vitro diagnosis device for the design of a PERSONALIZED immunosuppressant therapy to treat patients with chronic inflammatory diseases.

THE MARKET SIZE |

IMMUNOBIOGRAM® MARKET

GLOBAL IVD MARKET

Our core target is a market of 22M patients worldwide, patients with Renal Transplant and Rheumatoid Arthritis.

2 MillRenal

Transplants

20 MillRheumatoid

Arthritis

Annual profits

1% of world population,30% bad clinical evolution.

74 B$ in 2017 104 B$ in 2022**** Forecast

6,7% annual growth

OUR PRODUCT IMMUNOBIOGRAM® |

PROGNOSIS AND MONITORING KIT

Blood sample

Laboratory STANDARD- Fluorimeter

Biohope software web hosted (Algorithm & Database)

Biologicalprocess3-7 days

User Report: Self-explanatory, resistance/sensibility to di�erent drugs and recommendations. Generated by hospital´s immunology Lab and signed by authorized sta�.

COMPETITION |

only provides information about

global excess or scarcity of inmunosuppression.

IMMUNOBIOGRAM® is a IVD test based in a unique technology that will allow the selection of the optimal immunosuppressive therapy (combination of drugs / dosage) for each patient.

Immunobiogram® has not competitor providing similar information.

Which drugs? Which doses? For Renal Transplants

Rheumatoid Arthritis

MAJOR MILESTONES |

2016-2107 2019

2018 2020Prototypealready tested with beta user interface.

International Study in RAProduction Validation RT

InternationalStudy in RA

ProductionValidation RT

Publication + protection

European patent: 4 applications submitted.

Successfully finisheda National Study in RT with La Paz and Puerta de Hierro hospitals.

International Multicenter (4EU + 1 USA) Clinical Study

has been alreadylaunched for RT.National Study

in RA will be finished.

PCT Submission.

Sales RTCE Mark RT Sales RA2021

2022

BUSINESS MODEL STRATEGY |

Biohope business model is based on R&D for the Immunobiogram®, production will be externalized and commercialization will be thorough license agreements. Biohope will sell an IVD kit in 2020

Core BusinessR+DIP Strategy Medical A�airs RegulatoryBusiness Development

Production IVDkit externalized

Sales Immunobiogram®

kits

Clients / Partners agreements

Customers/Payers Users/DoctorsManufacturer

Biohope

Biohope

MANAGEMENT AND STAFF |

Dr. Isabel Portero, the founder of the company and currently the CEO, is a PhD in Medicine with a sound background in the biomedical field, who before founding Biohope acquired an extensive experience as Medical and R&D Director for di�erent hospitals, foundations, universities and biomedical/pharma companies, some of them in the Big Pharma industry like MSD or Roche. 

Flexible organizational structure.Cover all required areas to achieve milestones.Management has seniors profiles with proven results in their area of expertise.

Francisco TejeraFINANCIAL DIRECTOR

Ricardo BrageBUSINESS DEVELOPMENT

DIRECTOR

José RichterTECHNICAL AND

DEVELOPMENT DIRECTOR

Gerardo EntrenaLEGAL AFFAIRS

DIRECTOR OF BIOHOPE

STAFF

10 YEARS BUSINESS PLAN FOR 2027 |

600

500

400

300

200

100

02018 2019 2020 2021 2022 2023 2024 2025 2026 2027

13 3161

109

158

211

263

329

399

INCOME Gross Margin Cash at Banks Earned Value

€497 M

€307 M

€170 M

* Consolidated for 2 indications: Renal Transplant and Rheumatoid Arthritis

Gross Margin

Earned Value

INCOME

5 REASONS TO INVEST IN BIOHOPE |

1

Large, growing, profitable and unsatisfied market with no relevant direct competitors.

2

Breakthrough precision medine product adding value to physicians, patients and payers.

3

Solid business model with strong focus on core activities to achieve business and financial milestones.

4

High level of scientific partners and Public Institutions.

5

Strong professional and highly comitted Team.

PRECISION MEDICINE GIVING HOPE